Nervous System News and Research

Latest Nervous System News and Research

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.

12 Jul 2012

Research into “insulating” brain cells could help to cure neurodegenerative diseases such as ALS

Johns Hopkins researchers say they have discovered that the central nervous system's oligodendroglia cells, long believed to simply insulate nerves as they "fire" signals, are unexpectedly also vital to the survival of neurons. Damage to these insulators appears to contribute to brain injury in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease for the Yankee baseball great who died from the disease.

11 Jul 2012

Physicians need to know how chemical intolerance affects people: Study

Chemical intolerance contributes to the illnesses of 1 in 5 patients but the condition seldom figures in their diagnosis, according to clinical research directed by a UT Medicine San Antonio physician.

11 Jul 2012

Exposure to H1N1 vaccine in pregnancy does not increase risk of adverse fetal outcomes

In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.

11 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

SRI International receives DoD grant to develop novel therapy for MS

The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

11 Jul 2012

Lesogaberan development halts following disappointing results

Lesogaberan is only marginally superior to placebo in gastroesophageal reflux disease patients who are partially responsive to proton pump inhibitor therapy, results show.

10 Jul 2012

Specific cytokine levels altered in BD patients

Levels of certain cytokines differ between bipolar disorder patients and mentally healthy individuals, as well as between manic and euthymic patients with the mood disorder, results from a systematic review and meta-analysis show.

10 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Overproduction of hepcidin appears to impair maternal-fetal iron transfer

A growing number of studies imply that children born to obese mothers face health problems stemming from the womb.

10 Jul 2012

Maternal antiviral suppressive therapy may not be as effective as thought

Maternal antiviral suppressive therapy does not necessarily prevent the development of neonatal herpes simplex virus disease, warn researchers in The Journal of Pediatrics.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

Does alcohol kill brain cells?

Several origins have been suggested for the idea that alcohol kills brain cells. Some link it to the temperance movement, which called for prohibition of alcohol.

9 Jul 2012

Key difference between spinal regeneration in fish and mammals

Yona Goldshmit, Ph.D., is a former physical therapist who worked in rehabilitation centers with spinal cord injury patients for many years before deciding to switch her focus to the underlying science.

7 Jul 2012

Biological mechanisms behind appetite-suppressing effects of proteins

Frequently recommended in weight-loss diets, dietary proteins have proven effectiveness thanks to their appetite-suppressing effects. A team led by Gilles Mithieux, Director of Inserm's Unit 855 "Nutrition and the Brain" in Lyon, has managed to explain the biological mechanisms behind these properties.

7 Jul 2012

Toxins and cell death: Interview with Professor Denise Montell

There are multiple kinds of cell death. Cells can undergo programmed cell death, which is a series of events that undergoes a predictable order at certain times during development.

6 Jul 2012

Study shows cells from different Parkinson’s patients have unique drug responses

Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments.

5 Jul 2012